Industry landscapes
The companies, capital and talent shaping life sciences in Berlin. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
29 of 263 tracked companies have open roles.
103 of 263 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 115 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 37.9% of disclosed capital, while 60.8% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $19.58M | 8 | 8 |
| 2017 | $78.37M | 12 | 6 |
| 2018 | $43.65M | 17 | 8 |
| 2019 | $43.76M | 15 | 15 |
| 2020 | $118.29M | 14 | 11 |
| 2021 | $192.44M | 12 | 14 |
| 2022 | $122.62M | 7 | 14 |
| 2023 | $27.17M | 13 | 3 |
| 2024 | $83.38M | 4 | 9 |
| 2025 | $69.06M | 1 | 5 |
Share of all disclosed company funding.
162 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Boehringer Ingelheim Venture Fund and Kurma Partners and others.
Backed by Silicon Roundabout Ventures and SPRIND and others.
Backed by Fidelity Investments and Life Sciences Partners and others.
Backed by Octapharma.
Backed by RA Capital Management and Andera Partners and others.
Backed by Eckert Life Science Accelerator.
Backed by Four Rivers Group and Ashton Kutcher and others.
Backed by TVM Capital and Edmond de Rothschild and others.
Backed by NGN Capital and TVM Capital and others.
Backed by TVM Capital Life Science and 3i Group and others.
Backed by Tenaya Capital and Thrive Capital and others.
Backed by Athos and Mayo Clinic and others.
The measured Germany identity-to-filing probe did not produce a qualifying designated legal or national-ID join: designated German registry identities do not carry the LEI or ISIN used by bundesanzeiger facts; legal-name matching is prohibited.; The measured Germany identity-to-filing probe did not produce a qualifying designated legal or national-ID join: designated German registry identities do not carry the LEI or ISIN used by bundesanzeiger facts; legal-name matching is prohibited.
How the Berlin companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
5 of the 263 companies on this page carry a measured traffic record (1.9%); these are the largest of those, by monthly visits. The median among them is 255,965 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| ResearchGateresearchgate.net | 85,421,673 | 90 | 38.2% |
| FORMEL Skinformelskin.de | 295,801 | 43 | 91.5% |
| ScienceOpenscienceopen.com | 255,965 | 45 | 42.3% |
| BRAINEFFECTbrain-effect.com | 61,985 | 42 | 65.4% |
| Knauerknauer.net | 26,867 | 32 | 63.2% |
Visits and authority are third-party web estimates, not company-reported figures.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
17 companies hiring · $852M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Germany-based Aignostics is applying artificial intelligence to drug development, aiming to improve both efficiency and patient outcomes.
The biotechnology company Captain T Cell has completed a financing round and now has a total of 20 million euros to support its next generation of TCR T cell therapies for solid tumors in
NEW YORK — German cancer biomarker firm StratifAI said Tuesday that it has raised €12.5 million ($14.7 million) in an oversubscribed financing round.
has completed its financing announced in August, with €500,000 in cash.
Teleflex today said it agreed to divest the VI division to Teleflex for about €760 million (approximately $795 million).
Mologen AG (Germany;FSE:MGNG) Private placement of stock 0.55S €1.16 (US$1.58) Mologen issued the shares at €2.10 each against cash deposits of institutional investors (12/20)
Epigenomics raised €21M in a Series C round; investors were The Wellcome Trust Ltd., 3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital and tbg
3. Jerini raised €49.6M in an IPO of 15.5M shares on the Frankfurt Stock Exchange. Underwriters have an option to purchase up to 600,000 additional shares to cover overallotments.
The tissue-engineering company co.don AG plans to have the initial public offering of its shares next week on Frankfurt's Neuer Markt.
Chembio Diagnostics (Medford, New York) reported receiving private funding of $8.15 million of Series C 7% convertible preferred stock, together with warrants to purchase common stock.
Top 10 categories among 72 recorded events in the 24-month window.
2 companies with recorded IPO activity
4 tracked people moves
Appointment Chief Executive Officer
Appointment Chief Scientific Officer
Resignation Previously Chief Operating Officer
Appointment Chief Executive Officer
2 recorded customer wins
Customer: roche diagnosticsPharmaceuticals
Customer: Pall Corp.
2 recorded events
fully admitted to trading on regulated marketFrankfurt Stock Exchange
relevant investigating authorities
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| teleflex→Biotronik ↗ | Completed | 2025-07-02 | Not stated in snapshot |
| merlion pharmaceuticals→Combinature Biopharm ↗ | Completed | 2025-02-14 | Not stated in snapshot |
| Trigen Holdings→Procorde ↗ | Announced | 2025-02-14 | Not stated in snapshot |
| hologic→Somatex ↗ | Completed | 2025-02-14 | $64.0M |
| syscore→berlin heart gmbh ↗ | Announced | 2025-02-14 | Not stated in snapshot |
| Labforward→Lab Twin ↗ | Announced | 2024-09-17 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
2 postings in the preceding 12 months. The full 15-posting snapshot covers 9 employers.
0 tracked postings mention remote work.
4 postings specify a level.
Top skills across 15 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| berlin heart gmbh ↗ | 218 |
| Knauer ↗ | 190 |
| Vanguard ↗ | 155 |
| ResearchGate ↗ | 150 |
| BioGenes ↗ | 63 |
| Emp BIOTECH ↗ | 63 |
| Mologen ↗ | 38 |
| Epigenomics ↗ | 32 |
227 founders and chief executives across 158 companies.
Universities of Dresden PhD
Ex-CEO AplaGen, Kienbaum managemnet Consultants. Heinrich Heine University Düsseldorf
Ex-CEO Epigenomics, AltheaDx, RGTN, Enigma Diagnostics, Hologic, Leo Burnett. Purdue University Daniels School of Business BS 1992…
Researchgate, ex-Alemo Kommunikations, Universität Passau, 2007
Bayerisches Zentrum Fur Krebsforschung, ex-National Institutes Of Health, Charité - universitätsmedizin Berlin
CEO Ariceum Therapeutics, ex-CEO CatalYm, Apceth, Medigene AG. University of Tübingen PhD 1991
Ex-Caroobi. WHU – Otto Beisheim School of Management BS 2012, MS 2014
Freie Universität zu Berlin, Humboldt University of Berlin
Co-Founder LoNova, ex-Co-Founder & CEO Janus Genomics, UBS, German doctors finance. Julius Maximilians University of Wurzburg BA 2016, BS 2016
Ex-Co-Founder SixDoors, Plinga, Alazar. Berlin University of Applied Sciences Berlin BASc 1998, HHL Leipzig Graduate School of Management MBA 2000
Bebig Medical, ex-Siemens Healthineers, ex-Smiths Medical, National University of Singapore, 1993
Else Kroner Fresenius Center for Digital Health. ex-Co-Founder NEOSS, TalTech Tallinn University of Technology MS…
16 profiles with education records.
3 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
1,838 articles in the measured 12-month window.
Life Sciences coverage tagged Berlin · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 530 |
| 2021Q3 | 467 |
| 2021Q4 | 428 |
| 2022Q1 | 444 |
| 2022Q2 | 390 |
| 2022Q3 | 321 |
| 2022Q4 | 408 |
| 2023Q1 | 343 |
| 2023Q2 | 463 |
| 2023Q3 | 351 |
| 2023Q4 | 444 |
| 2024Q1 | 562 |
| 2024Q2 | 556 |
| 2024Q3 | 452 |
| 2024Q4 | 395 |
| 2025Q1 | 2,158 |
| 2025Q2 | 324 |
| 2025Q3 | 391 |
| 2025Q4 | 667 |
| 2026Q1 | 465 |
Article volume measures coverage, not market sales.
120 recorded company events across 18 companies; percentages use that event total.
Life Sciences coverage tagged Berlin · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Germany comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 121 | 56 | 116% |
| vaccine trials | 121 | 62 | 95% |
| vaccination campaigns | 96 | 35 | 174% |
| vaccine immunogenicity | 94 | 46 | 104% |
| mass vaccination sites | 75 | 16 | 369% |
| smart packaging | 75 | 27 | 178% |
| temperature-sensitive packaging | 66 | 20 | 230% |
| anti-counterfeiting packaging | 59 | 21 | 181% |
| continuous manufacturing | 46 | 14 | 229% |
| crispr applications | 40 | 28 | 43% |
| diagnostic biotechnology | 84 | 202 | -58% |
| stem cell banking | 128 | 202 | -37% |
| biosimilar approval | 116 | 198 | -41% |
| cell-based therapies | 82 | 170 | -52% |
| gene therapy rare diseases | 108 | 166 | -35% |
Germany comparison coverage
vaccine candidates, vaccine trials, stem cell banking
42.8% critical · 42.2% positivetherapeutic development funding, biotech incubator, vaccine innovation funding
47.7% critical · 51.4% positivebiosimilar market entry, generic drug approval, drug distribution
31.7% critical · 46.3% positiveLife Sciences coverage tagged Berlin. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Issues related to microbial hazards, nutritional quality, and health impacts of processed foods.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Barriers in controlling gene activity, mRNA delivery, and cell‑culture models for disease treatment.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Problems in improving nutrient uptake, breeding efficiency, and securing stable food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Complexities of host‑pathogen interactions, fungicide use, and integrated pest control strategies.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Widespread resistance in humans, livestock, and the environment limiting treatment options.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Diverse, less‑focused research areas spanning molecular order, metabolism, and interdisciplinary studies.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Caution about in‑vitro and in‑vivo models revealing stress responses to contaminants.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Need for careful implementation of genomic tools to avoid unintended trait consequences.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Risks and benefits of novel feed compounds for livestock performance and consumer safety.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Potential hazards from chemicals and novel ingredients requiring thorough safety evaluation.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Uncertainties in how gene‑editing and stress affect genomic stability in therapeutic contexts.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Interactions between antibiotics, biocides, and metals that may amplify resistance spread.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Challenges in dosing and ecological impacts when combating evolving pesticide resistance.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Promising uses of fluorescent antibodies and flow cytometry for in‑vivo diagnostics.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Opportunities in controlling apoptosis and cell growth through targeted gene knockdown.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Development of antioxidant‑rich ingredients for health‑promoting, sustainable diets.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Emerging tools leveraging DNA methylation and miRNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Exploration of plant‑derived compounds and postbiotic products to combat resistant microbes.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Advances in QTL mapping and selection to boost crop yield and trait performance.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Utilizing microbial fermentation and agri‑food waste for greener energy and material production.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.2% |
| Promising | 30.4% | 37.2% |
| Breakthrough | 14.1% | 26.3% |
| Problem-identifying | 8.3% | 9.7% |
| Cautionary | 3.5% | 4.7% |
| Comparative | 2.4% | 4.0% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗